{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-24-100709","form_type":"8-K","ticker":"TRAW","cik":"0001130598","company_name":"Traws Pharma, Inc.","filed_at":"2024-09-17T23:59:59+00:00","discovered_at":"2026-05-14T18:03:12.246917+00:00","generated_at":"2026-05-31T04:09:47.910411+00:00","sec_items":["5.02","5.03","5.07","5.08","8.01","9.01"],"event_type":"regulatory","sentiment":"neutral","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Traws Pharma approves 1-for-25 reverse stock split, regains Nasdaq equity compliance","bullets":["Board approved 1-for-25 reverse split; effective Sept 20, trading split-adjusted Sept 23.","Authorized shares increased from 125M to 250M; stockholders approved conversion of Series C Preferred.","Director James Marino resigned; Luba Greenwood appointed to board and committees.","Company believes it now satisfies Nasdaq $2.5M stockholders' equity requirement after conversion; delisting risk remains.","Annual meeting set for Oct 31, 2024; shareholder proposals due Sept 26, 2024."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-24-100709","json":"https://secwatch.observer/filing/0001104659-24-100709.json","markdown":"https://secwatch.observer/filing/0001104659-24-100709.md","text":"https://secwatch.observer/filing/0001104659-24-100709.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1130598/000110465924100709/0001104659-24-100709-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1130598/000110465924100709/tm2424247d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-31T04:09:47.910411+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"dfe4998288","claim":"James J. Marino resigned as Director at Traws Pharma, Inc..","evidence_excerpt":"On September 16, 2024, James J. Marino, a member of the Board of Directors (the “Board”) of Traws Pharma, Inc. (the “Company”), resigned as a director.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1130598/000110465924100709/0001104659-24-100709-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"resigned"},{"label":"Role","value":"Director"}],"fact_type":"executive_change"},{"claim_id":"e088fd1c2d","claim":"Luba Greenwood was appointed as Director at Traws Pharma, Inc..","evidence_excerpt":"the Board appointed Luba Greenwood to the Board to fill the vacancy created by Mr. Marino’s resignation with a term expiring at the Company’s 2024 annual meeting of stockholders.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1130598/000110465924100709/0001104659-24-100709-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Director"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}